Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Rhea-AI Summary

Milestone Pharmaceuticals (Nasdaq: MIST) announced it will present a moderated poster at the American College of Cardiology annual meeting (ACC25) in Chicago from March 29-31, 2025. The presentation will focus on clinical data for etripamil, showcasing its potential to convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to normal sinus rhythm.

According to Chief Medical Officer Dr. David Bharucha, the data demonstrates that successful conversion of earlier PSVT episodes predicts success in subsequent treatments. The findings support etripamil's potential use for successive PSVT episodes, pending approval, aiming to improve patient experience and quality of life.

Positive

• Clinical data shows positive results for etripamil in treating multiple PSVT episodes
• Early treatment success predicts effectiveness in subsequent episodes

Negative

• None.

News Market Reaction

-2.01%

1 alert

-2.01% News Effect

On the day this news was published, MIST declined 2.01%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29^th to 31^st, 2025 in Chicago, Illinois.

“This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion in subsequent ones,” said David Bharucha, MD PhD FACC, Chief Medical Officer of Milestone Pharmaceuticals. “These new data support the opportunity to use etripamil, if approved, for successive PSVT episodes underscoring a potentially positive impact on patients’ experience and quality of life, in line with Milestone’s commitment to providing a convenient and effective therapeutic option for PSVT.”

ACC Presentation Details:
Moderated Poster Presentation Title:	Consistency and Predictiveness of Conversion Among Multiple Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) Treated with Etripamil: Outcomes from the NODE-303 trial
Presenter:	James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time:	Sunday, March 30, 2025, 11:42 – 11:49 AM Central Time
Location:	Moderated Poster Theater 1

A copy of the abstract can be viewed on the ACC25 website, on the Online Planner here.

About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will", “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA; the potential of etripamil to (i) successfully convert multiple episodes of PSVT to restore normal sinus rhythm and (ii) have a positive impact on patients’ experience and quality of life; and other statements not related to historical fact. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications; general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad; risks related to pandemics and public health emergencies; and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2024, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Kim Fox, Vice President, Communications, kfox@milestonepharma.com

Investor Relations: Kevin Gardner, kgardner@lifesciadvisors.com

FAQ

What clinical data will Milestone Pharmaceuticals (MIST) present at ACC25?

Milestone will present data showing etripamil's potential to convert multiple PSVT episodes to normal sinus rhythm, with early success predicting subsequent treatment effectiveness.

When and where will Milestone Pharmaceuticals (MIST) present at the ACC 2025 conference?

Milestone will present a moderated poster at ACC25 in Chicago, Illinois, from March 29-31, 2025.

What are the key findings of etripamil's clinical data for PSVT treatment?

The data shows etripamil can successfully convert multiple PSVT episodes to normal sinus rhythm, with early episode conversion predicting success in later treatments.

How could etripamil benefit PSVT patients according to MIST's presentation?

If approved, etripamil could provide a convenient and effective therapeutic option for treating successive PSVT episodes, potentially improving patient experience and quality of life.